NCT05405491 Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
| NCT ID | NCT05405491 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Pneumonia, Ventilator-Associated |
| Study Type | INTERVENTIONAL |
| Enrollment | 31 participants |
| Start Date | 2023-03-28 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 31 participants in total. It began in 2023-03-28 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RESPIRE is a randomized, unblinded, controlled study to measure the impact of a strategy based on a PCR test on the adjustment of antimicrobial therapy in immunocompromised patients suspected with ventilator-associated or hospital-acquired pneumonia (VAP/HAP) requiring mechanical ventilation (MV) in Intensive Care Unit (ICU). The gold-standard microbiological diagnostic method for pneumonia in the ICU is based on culture identification and antimicrobial susceptibility testing. Results are obtained in several days after the initiation of empiric antimicrobial therapy, exposing patients to a potential inappropriate broad-spectrum antimicrobial treatment. We aim to measure the impact of a PCR-based strategy to improve the percentage of patients with VAP or HAP receiving targeted antimicrobial therapy 24 hours after diagnosis compared to standard care
Eligibility Criteria
Inclusion Criteria: * Adult immunocompromised patients hospitalized in ICU with suspected VAP or HAP requiring MV Exclusion Criteria: * No immunodeficiency Moribund patients (SAPS II \> 90) Pregnant women Refuse to participate to the study
Contact & Investigator
Marion HOUARD, MD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT05405491 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pneumonia, Ventilator-Associated. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05405491 currently recruiting?
Yes, NCT05405491 is actively recruiting participants. Contact the research team at marion.houard@chru-lille.fr for enrollment information.
Where is the NCT05405491 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT05405491 clinical trial?
NCT05405491 is sponsored by University Hospital, Lille. The principal investigator is Marion HOUARD, MD at University Hospital, Lille. The trial plans to enroll 31 participants.